G Sugranyes1, J L Thompson, C M Corcoran. 1. Servei de Psiquiatria i Psicologia Infantil i Juvenil, Institut de Neurociències, Hospital Clínic de Barcelona, c. Villarroel 140, 08015 Barcelona, Spain. 39987gse@comb.cat
Abstract
AIM: Increased basal cortisol secretion has been associated with heightened clinical risk for psychosis, and among at-risk individuals, has been variably related to positive and mood symptoms, as well as clinical outcome. METHODS: Basal salivary cortisol secretion was assessed in 33 patients at clinical high risk (CHR) for psychosis (21 medication-free and 12 taking a serotonin reuptake inhibitor and/or atypical antipsychotic), and 13 healthy controls. Among the CHR patients, we also examined associations of basal salivary cortisol with symptoms (positive, negative, mood, stress sensitivity) and clinical outcome. RESULTS: Basal salivary cortisol secretion was significantly higher in CHR patients who were medication-free compared to CHR patients taking medications and to healthy controls. In this small cohort, basal salivary cortisol secretion was associated at trend level with stress sensitivity, and was not significantly related to other symptoms. CONCLUSIONS: Our finding of elevated basal cortisol secretion in CHR patients supports the premise that excess activation of the HPA axis and/or neuroendocrine abnormalities characterize the psychosis risk state for at least a subset of patients. Our findings further suggest that psychotropic medications may have a normalizing effect on HPA-axis dysfunction in CHR patients, which could potentially inform intervention strategies for the prodrome.
AIM: Increased basal cortisol secretion has been associated with heightened clinical risk for psychosis, and among at-risk individuals, has been variably related to positive and mood symptoms, as well as clinical outcome. METHODS: Basal salivary cortisol secretion was assessed in 33 patients at clinical high risk (CHR) for psychosis (21 medication-free and 12 taking a serotonin reuptake inhibitor and/or atypical antipsychotic), and 13 healthy controls. Among the CHRpatients, we also examined associations of basal salivary cortisol with symptoms (positive, negative, mood, stress sensitivity) and clinical outcome. RESULTS: Basal salivary cortisol secretion was significantly higher in CHRpatients who were medication-free compared to CHRpatients taking medications and to healthy controls. In this small cohort, basal salivary cortisol secretion was associated at trend level with stress sensitivity, and was not significantly related to other symptoms. CONCLUSIONS: Our finding of elevated basal cortisol secretion in CHRpatients supports the premise that excess activation of the HPA axis and/or neuroendocrine abnormalities characterize the psychosis risk state for at least a subset of patients. Our findings further suggest that psychotropic medications may have a normalizing effect on HPA-axis dysfunction in CHRpatients, which could potentially inform intervention strategies for the prodrome.
Authors: Martino Belvederi Murri; Carmine M Pariante; Paola Dazzan; Nilay Hepgul; Andrew S Papadopoulos; Patricia Zunszain; Marta Di Forti; Robin M Murray; Valeria Mondelli Journal: Psychoneuroendocrinology Date: 2011-09-17 Impact factor: 4.905
Authors: P Habets; D Collip; I Myin-Germeys; E Gronenschild; S van Bronswijk; P Hofman; T Lataster; M Lardinois; N A Nicolson; J van Os; M Marcelis Journal: Psychol Med Date: 2011-12-01 Impact factor: 7.723
Authors: Romina Mizrahi; Jean Addington; Pablo M Rusjan; Ivonne Suridjan; Alvina Ng; Isabelle Boileau; Jens C Pruessner; Gary Remington; Sylvain Houle; Alan A Wilson Journal: Biol Psychiatry Date: 2011-11-30 Impact factor: 13.382
Authors: P Putignano; A Dubini; P Toja; C Invitti; S Bonfanti; G Redaelli; D Zappulli; F Cavagnini Journal: Eur J Endocrinol Date: 2001-08 Impact factor: 6.664
Authors: Valeria Mondelli; Paola Dazzan; Nilay Hepgul; Marta Di Forti; Monica Aas; Alessandro D'Albenzio; Marco Di Nicola; Helen Fisher; Rowena Handley; Tiago Reis Marques; Craig Morgan; Serena Navari; Heather Taylor; Andrew Papadopoulos; Katherine J Aitchison; Robin M Murray; Carmine M Pariante Journal: Schizophr Res Date: 2009-09-13 Impact factor: 4.939
Authors: C W Holtzman; H D Trotman; S M Goulding; A T Ryan; A N Macdonald; D I Shapiro; J L Brasfield; E F Walker Journal: Neuroscience Date: 2013-01-05 Impact factor: 3.590
Authors: Sandra M Goulding; Carrie W Holtzman; Hanan D Trotman; Arthur T Ryan; Allison N Macdonald; Daniel I Shapiro; Joy L Brasfield; Elaine F Walker Journal: Child Adolesc Psychiatr Clin N Am Date: 2013-06-18
Authors: Vijay Anand Mittal; Joseph Michael Orr; Andrea Pelletier; Derek James Dean; Ashley Smith; Jessica Lunsford-Avery Journal: Psychiatry Res Date: 2013-01-16 Impact factor: 3.222
Authors: Samantha R Eck; Cory S Ardekani; Madeleine Salvatore; Sandra Luz; Eric D Kim; Charleanne M Rogers; Arron Hall; Demetrius E Lee; Sydney T Famularo; Seema Bhatnagar; Debra A Bangasser Journal: Eur J Neurosci Date: 2019-11-24 Impact factor: 3.386